Compare HXL & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HXL | RNA |
|---|---|---|
| Founded | 1946 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 227.6M |
| IPO Year | 1994 | 2025 |
| Metric | HXL | RNA |
|---|---|---|
| Price | $79.08 | $13.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 20 |
| Target Price | ★ $81.73 | $69.26 |
| AVG Volume (30 Days) | ★ 1.1M | 1.1M |
| Earning Date | 04-20-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,893,900,000.00 | N/A |
| Revenue This Year | $10.20 | $88.12 |
| Revenue Next Year | $12.65 | $18.11 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $45.28 | $11.95 |
| 52 Week High | $95.22 | $73.06 |
| Indicator | HXL | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 38.06 | 9.41 |
| Support Level | $76.70 | $13.06 |
| Resistance Level | $79.20 | $72.75 |
| Average True Range (ATR) | 2.44 | 0.62 |
| MACD | -0.42 | 1.88 |
| Stochastic Oscillator | 21.16 | 37.39 |
Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use in the commercial aerospace, defense, and high-performance automotive markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engines, and other components and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (40% of 2024 sales) and Boeing (15% of 2024 sales; 25% before the pandemic) and their respective subcontractors.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.